Kenneth Hillan
2022
In 2022, Kenneth Hillan earned a total compensation of $3.2M as Chief Therapeutics Officer at 23andMe Holding Co., a 1% decrease compared to previous year.
Compensation breakdown
| Option Awards | $1,549,205 |
|---|---|
| Salary | $578,333 |
| Stock Awards | $1,070,455 |
| Other | $3,865 |
| Total | $3,201,858 |
Hillan received $1.5M in option awards, accounting for 48% of the total pay in 2022.
Hillan also received $578.3K in salary, $1.1M in stock awards and $3.9K in other compensation.
Rankings
In 2022, Kenneth Hillan's compensation ranked 1,133rd out of 5,753 executives tracked by ExecPay. In other words, Hillan earned more than 80.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,133 out of 5,753 | 80th |
Division Manufacturing | 546 out of 3,133 | 83rd |
Major group Chemicals And Allied Products | 199 out of 1,419 | 86th |
Industry group Drugs | 179 out of 1,320 | 86th |
Industry Pharmaceutical Preparations | 135 out of 966 | 86th |
Source: SEC filing on July 15, 2022.
Hillan's colleagues
We found four more compensation records of executives who worked with Kenneth Hillan at 23andMe Holding Co. in 2022.